CD34 and myelodysplastic syndrome: The first and simplest approach consist ofco-injecting patient-derived autologous/allogeneic MSCs with MDS cells (CD34+ BM cells or CD3-depleted BM cells) directly into the medullary cavity of sublethally irradiated NSG mice [51,66].